BACKGROUND: Hypertension and renal injury are common complications of type 2 diabetes mellitus (T2DM). Hyperglycemia stimulates renal proximal tubular angiotensinogen (AGT) expression via elevated oxidative stress contributing to the development of high blood pressure and diabetic nephropathy. The sodium glucose cotransporter 2 (SGLT2) in proximal tubules is responsible for the majority of glucose reabsorption by renal tubules. We tested the hypothesis that SGLT2 inhibition with canagliflozin (CANA) prevents intrarenal AGT augmentation and ameliorates kidney injury and hypertension in T2DM. METHODS: We induced T2DM in New Zealand obese mice with a high fat diet (DM, 30% fat) with control mice receiving regular fat diet (ND, 4% fat). When DM mice exhibited > 350 mg/dL blood glucose levels, both DM- and ND-fed mice were treated with 10 mg/kg/day CANA or vehicle by oral gavage for 6 weeks. We evaluated intrarenal AGT, blood pressure, and the development of kidney injury. RESULTS: Systolic blood pressure in DM mice (133.9 ± 2.0 mm Hg) was normalized by CANA (113.9 ± 4.0 mm Hg). CANA treatment ameliorated hyperglycemia-associated augmentation of renal AGT mRNA (148 ± 21 copies/ng RNA in DM, and 90 ± 16 copies/ng RNA in DM + CANA) and protein levels as well as elevation of urinary 8-isoprostane levels. Tubular fibrosis in DM mice (3.4 ± 0.9-fold, fibrotic score, ratio to ND) was suppressed by CANA (0.9 ± 0.3-fold). Furthermore, CANA attenuated DM associated increased macrophage infiltration and cell proliferation in kidneys of DM mice. CONCLUSIONS: CANA prevents intrarenal AGT upregulation and oxidative stress and which may mitigate high blood pressure, renal tubular fibrosis, and renal inflammation in T2DM.
BACKGROUND:Hypertension and renal injury are common complications of type 2 diabetes mellitus (T2DM). Hyperglycemia stimulates renal proximal tubular angiotensinogen (AGT) expression via elevated oxidative stress contributing to the development of high blood pressure and diabetic nephropathy. The sodium glucose cotransporter 2 (SGLT2) in proximal tubules is responsible for the majority of glucose reabsorption by renal tubules. We tested the hypothesis that SGLT2 inhibition with canagliflozin (CANA) prevents intrarenal AGT augmentation and ameliorates kidney injury and hypertension in T2DM. METHODS: We induced T2DM in New Zealand obesemice with a high fat diet (DM, 30% fat) with control mice receiving regular fat diet (ND, 4% fat). When DMmice exhibited > 350 mg/dL blood glucose levels, both DM- and ND-fed mice were treated with 10 mg/kg/day CANA or vehicle by oral gavage for 6 weeks. We evaluated intrarenal AGT, blood pressure, and the development of kidney injury. RESULTS: Systolic blood pressure in DMmice (133.9 ± 2.0 mm Hg) was normalized by CANA (113.9 ± 4.0 mm Hg). CANA treatment ameliorated hyperglycemia-associated augmentation of renal AGT mRNA (148 ± 21 copies/ng RNA in DM, and 90 ± 16 copies/ng RNA in DM + CANA) and protein levels as well as elevation of urinary 8-isoprostane levels. Tubular fibrosis in DMmice (3.4 ± 0.9-fold, fibrotic score, ratio to ND) was suppressed by CANA (0.9 ± 0.3-fold). Furthermore, CANA attenuated DM associated increased macrophage infiltration and cell proliferation in kidneys of DMmice. CONCLUSIONS:CANA prevents intrarenal AGT upregulation and oxidative stress and which may mitigate high blood pressure, renal tubular fibrosis, and renal inflammation in T2DM.
Authors: Xiaoxin X Wang; Jonathan Levi; Yuhuan Luo; Komuraiah Myakala; Michal Herman-Edelstein; Liru Qiu; Dong Wang; Yingqiong Peng; Almut Grenz; Scott Lucia; Evgenia Dobrinskikh; Vivette D D'Agati; Hermann Koepsell; Jeffrey B Kopp; Avi Z Rosenberg; Moshe Levi Journal: J Biol Chem Date: 2017-02-14 Impact factor: 5.157
Authors: Tusty-Jiuan Hsieh; Pierre Fustier; Chih-Chang Wei; Shao-Ling Zhang; Janos G Filep; Shiow-Shiu Tang; Julie R Ingelfinger; I George Fantus; Pavel Hamet; John S D Chan Journal: J Endocrinol Date: 2004-12 Impact factor: 4.286
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Naoki Kojima; Jan M Williams; Tiffani N Slaughter; Sota Kato; Teisuke Takahashi; Noriyuki Miyata; Richard J Roman Journal: Physiol Rep Date: 2015-07
Authors: Virginia Reverte; Venkateswara R Gogulamudi; Carla B Rosales; Diego C Musial; Sabrina R Gonsalez; Alberto J Parra-Vitela; Michelle Galeas-Pena; Venkata N Sure; Bruna Visniauskas; Sarah H Lindsey; Prasad V G Katakam; Minolfa C Prieto Journal: J Diabetes Complications Date: 2019-10-05 Impact factor: 2.852
Authors: Ryousuke Satou; Michael W Cypress; T Cooper Woods; Akemi Katsurada; Courtney M Dugas; Vivian A Fonseca; L Gabriel Navar Journal: Am J Physiol Renal Physiol Date: 2019-11-04
Authors: Jessica Gooding; Lei Cao; Faihaa Ahmed; Jean-Marie Mwiza; Mizpha Fernander; Courtney Whitaker; Zach Acuff; Susan McRitchie; Susan Sumner; Elimelda Moige Ongeri Journal: Am J Physiol Renal Physiol Date: 2019-08-14
Authors: Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney Journal: Endocr Rev Date: 2020-04-01 Impact factor: 19.871
Authors: Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney Journal: Curr Diab Rep Date: 2022-05-28 Impact factor: 4.810
Authors: George Bakris; Megumi Oshima; Kenneth W Mahaffey; Rajiv Agarwal; Christopher P Cannon; George Capuano; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Hiddo J L Heerspink; Adeera Levin; Bruce Neal; Richard Oh; Carol Pollock; Norman Rosenthal; David C Wheeler; Hong Zhang; Bernard Zinman; Meg J Jardine; Vlado Perkovic Journal: Clin J Am Soc Nephrol Date: 2020-11-19 Impact factor: 8.237
Authors: Kana N Miyata; Chao-Sheng Lo; Shuiling Zhao; Xin-Ping Zhao; Isabelle Chenier; Michifumi Yamashita; Janos G Filep; Julie R Ingelfinger; Shao-Ling Zhang; John S D Chan Journal: Diabetologia Date: 2021-08-09 Impact factor: 10.122